MBF-015 is under clinical development by Medibiofarma and currently in Phase II for Huntington Disease. According to GlobalData, Phase II drugs for Huntington Disease have a 41% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how MBF-015’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
MBF-015 overview
MBF-015 is under development for the treatment of synaptopathies (huntington disease, alzheimer's disease and parkinson's disease) . It acts by targeting histone deacetylase 1/2 (HDAC 1/2). It ia administered through oral route.
Medibiofarma overview
Medibiofarma is a biotechnology company that develops novel drugs for the treatment of cancer. It focuses on virtual drug design, medicinal chemistry, in vitro pharmacology, and intellectual property. The company is headquartered in Noain, Navarra, Spain.
For a complete picture of MBF-015’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
